Website maintenance took place on Thursday 30 April 2026. If you experience any issues, please contact us.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (281)
- COVID-19 (163)
- Safety monitoring and information (108)
- Compliance and enforcement (78)
- Legislation (77)
- Manufacturing (57)
- Vaping hub (56)
- Labelling and packaging (38)
- Import and export (32)
- Scheduling (national classification system) (27)
- Medicinal cannabis hub (25)
- Sunscreens (20)
- Weight loss products (15)
- Shortages and supply disruptions (13)
- Committees and advisory bodies (9)
- Cosmetics (5)
- Unique Device Identification (UDI) hub (4)
- Clinical trials (3)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
1259 result(s) found, displaying 1126 to 1150
-
BlogIs there a hangover cure? Essential reading for anyone visited by spirits these holidays.
-
Safety updatesInfliximab and mycosis fungoides, infliximab and lupus-like syndrome, and medicine shortages mandatory reporting
-
Media releasesThis legal action follows an investigation by the Therapeutic Goods Administration
-
Regulatory decision noticesTGO 100 has been registered on the Federal Register of Legislation. It commences on 8 December 2018, repealing and replacing TGO 98
-
Media releasesThere will not be a decision announced on scheduling of alkyl nitrites on 29 November 2018. Further public consultation will be undertaken.
-
News articlesReforms relating to accessing unapproved products include modifications to the Special Access Scheme and Authorised Prescriber scheme to allow streamlined access to certain unapproved therapeutic products.
-
News articlesThe complementary medicine regulatory reforms include changes that will create a new approval pathway for listed complementary medicines and increase availability of information to support consumer decisions.
-
News articlesThe prescription medicines regulatory reforms include changes that will bring medicines to market sooner in Australia, while maintaining a robust framework for safety, quality and efficacy.
-
News articlesReforms to TGA advisory committees include changes that provide greater efficiencies and a reduction in the number of statutory advisory committees that provide independent advice to the TGA.
-
Safety updatesStandards minimise risk of misconnections; eltrombopag interference with test results; amniotic fluid tests
-
News articlesCabozantinib (CABOMETYX) is the first medicine to be registered via the new COR-A pathway
-
BlogWhat is the TGA? Learn why and how we regulate medicines and medical devices.
-
Media releasesJoint media release between Australian Border Force and Therapeutic Goods Administration
-
BlogSome retailers try to use disclaimers like 'for research purposes only' to sell an illegal product, but these disclaimers don't change the law.
-
Safety updatesCase studies in Incident Report Investigations; review of reusable biopsy forceps devices; care required with patient lifters
-
Media releasesThe TGA has launched a web hub to help consumers and health professionals find information on transvaginal (urogynaecological) surgical mesh.
-
Safety updatesNew warning labels for neuromuscular blocking agents; local anaesthetic systemic toxicity; off-label use of atropine
-
BlogGeorgia's story explains how to spot the warning signs for the breast implant associated cancer BIA-ALCL.
-
Regulatory decision noticesTGA issues advertising direction
-
Media releasesToday we celebrate the official launch of the TGA Facebook page
-
Safety updatesThe TGA completed a desktop review of selected listed sunscreen products.
-
Safety updatesBe aware of cross-reactivity with home-use self-test ovulation kits, TGA undertakes product safety review into intragastric balloon systems
-
Media releasesOur annual survey measures satisfaction with a range of services and activities including our role and performance
-
Media releasesApalutamide (Erlyand) is the first medicine approved via ACSS Consortium’s NCE working group
-
Media releasesConsumers can now report dodgy ads for medicines and medical devices through a single online form